Primary Care Alliance

Primary Care Alliance

Contact Us Join Today

Home | Archives for mNEXSPIKE

Moderna’s mNEXSPIKE Webinar | June 16-17, 2026

Moderna is hosting a webinar for health professionals on updates on its mNEXSPIKE (COVID-19, mRNA) on Tuesday, June 16, 2026, from 3:00 PM to 4:00 PM ET and Wednesday, June 17, 2026, from 12:00 PM to 1:00 PM ET.

In both sessions, presenters Dr. McKinney and Dr. Middleton will “review the evolving disease landscape, discuss the latest data on mNEXSPIKE (COVID-19 Vaccine, mRNA), and share clinical perspectives and best practices to support strong COVID-19 vaccine recommendations.” To view more details on Moderna’s upcoming webinar, click here.

Moderna’s mNexspike was approved by the FDA on May 31, 2025, for patients 65 years and older. Additionally, mNexspike is approved to be administered to patients 12 years and older with a high-risk condition. Asthma, cancer, diabetes, heart conditions, HIV, mental health conditions, obesity and many other diagnoses fall under the CDC’s list of high-risk conditions. To see the CDC’s complete list of high-risk conditions, please go here.

To register, click the buttons below to sign up for your preferred session

Tuesday, June 16, 2026
3:0‌0 to 4:0‌0 PM ET

Register Now

Wednesday, June 17, 2026
12:0‌0 to 1:0‌0 PM ET

Register Now

FDA Approves Merck’s Enflonsia

The FDA approved Merck’s Enflonsia (clesrovimab-cfor) which is a monoclonal antibody designed to protect infants against respiratory syncytial virus (RSV) disease. Enflonsia can be given to infants during their first RSV season. Merck’s Enflonsia is similar to Sanofi’s Beyfortus. PCA will begin offering Enflonsia to our members through our Merck program when it becomes available to purchase.

Although Enflonsia is a monoclonal antibody and not a vaccine, we anticipate the ACIP will make recommendations on how Enflonsia should be used. Payer coverage typically occurs within a year after ACIP recommendations are published in the MMWR. We will provide additional information as it becomes available.

To learn more, click here to read Merck’s news release.

FDA Approves Moderna’s new COVID-19 Vaccine mNEXSPIKE

This fall PCA hopes to offer members the opportunity to purchase Moderna’s new COVID-19 vaccine mNEXSPIKE for their patients 65 years and older and high-risk individuals aged 12-64 years. According to Moderna’s press release, this new COVID-19 vaccine “showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older” compared to Spikevax, Moderna’s original COVID-19 vaccine.

Once a new vaccine has been approved by the FDA, it is reviewed by the ACIP. This committee will make recommendations on how this vaccine should be used. Payer coverage typically occurs after ACIP recommendations are published in the MMWR. We will provide additional information as it becomes available.

To learn more, click here to read Moderna’s news release.

Address

240 N. East Promontory Suite 200
Farmington, UT 84025

Directions

CONTACT US

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
*